1. Home
  2. CRVO
  3. CRVO News

Latest CervoMed Inc. (CRVO) News on November 15, 2025

CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
CRVO

GlobeNewswire

5 days ago

CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates
CRVO

Zacks

7 days ago

CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates

Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains?
CRVO

Zacks

8 days ago

Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains?

Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Beats Revenue Estimates
CRVO

Zacks

8 days ago

Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Beats Revenue Estimates

CRVO

MT Newswires

9 days ago

CervoMed Shares Rise After HC Wainwright Upgrade

CRVO

MT Newswires

10 days ago

HC Wainwright Upgrades CervoMed to Buy From Neutral, Adjusts Price Target to $25 From $11

CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies
CRVO

GlobeNewswire

11 days ago

CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies

Here's Why We're Watching CervoMed's (NASDAQ:CRVO) Cash Burn Situation
CRVO

Simply Wall St.

15 days ago

Here's Why We're Watching CervoMed's (NASDAQ:CRVO) Cash Burn Situation

CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley
CRVO

GlobeNewswire

18 days ago

CervoMed Strengthens Board with Appointment of Life Sciences Business Strategy Leader David Quigley

Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last?
CRVO

Zacks

a month ago

Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last?

CRVO

MT Newswires

a month ago

CervoMed Says Neflamapimod Shows Effective in Treating Dementia with Lewy Bodies Without Alzheimer's Overlap

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies
CRVO

GlobeNewswire

a month ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer
CRVO

GlobeNewswire

a month ago

CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
CRVO

GlobeNewswire

a month ago

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization
CRVO

GlobeNewswire

5 months ago

CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization

CervoMed First Quarter 2025 Earnings: Beats Expectations
CRVO

Simply Wall St.

6 months ago

CervoMed First Quarter 2025 Earnings: Beats Expectations

CRVO

MT Newswires

6 months ago

Chardan Adjusts Price Target on CervoMed to $15 From $14, Maintains Buy Rating

CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates
CRVO

Zacks

6 months ago

CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
CRVO

GlobeNewswire

6 months ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference
CRVO

GlobeNewswire

6 months ago

CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference

Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025
CRVO

GlobeNewswire

7 months ago

Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)
CRVO

GlobeNewswire

8 months ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)

Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts?
CRVO

Insider Monkey

8 months ago

Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts?

CervoMed Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
CRVO

Simply Wall St.

8 months ago

CervoMed Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

CervoMed Inc. (CRVO): The Best Short-Term Stock to Buy Right Now
CRVO

Insider Monkey

8 months ago

CervoMed Inc. (CRVO): The Best Short-Term Stock to Buy Right Now

CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
CRVO

GlobeNewswire

8 months ago

CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates

Why CervoMed Inc. (CRVO) Soared Last Week?
CRVO

Insider Monkey

8 months ago

Why CervoMed Inc. (CRVO) Soared Last Week?

CervoMed upgraded to Buy at JonesResearch on more confidence in DLB program
CRVO

TipRanks

8 months ago

CervoMed upgraded to Buy at JonesResearch on more confidence in DLB program

We Think CervoMed (NASDAQ:CRVO) Can Afford To Drive Business Growth
CRVO

Simply Wall St.

8 months ago

We Think CervoMed (NASDAQ:CRVO) Can Afford To Drive Business Growth

CRVO

MT Newswires

8 months ago

Chardan Upgrades CervoMed to Buy From Neutral, Price Target is $14

CRVO

MT Newswires

8 months ago

Brookline Capital Upgrades CervoMed to Buy From Hold, Price Target is $16

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
CRVO

GlobeNewswire

8 months ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Why CervoMed (CRVO) Is Advancing Today
CRVO

Insider Monkey

9 months ago

Why CervoMed (CRVO) Is Advancing Today

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
CRVO

GlobeNewswire

9 months ago

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

CervoMed to Present at the 8th International Lewy Body Dementia Conference
CRVO

GlobeNewswire

10 months ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

CervoMed price target lowered to $4 from $45 at Roth MKM
CRVO

TipRanks

a year ago

CervoMed price target lowered to $4 from $45 at Roth MKM

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CRVO

GlobeNewswire

a year ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRVO

MT Newswires

a year ago

Morgan Stanley Downgrades CervoMed to Underweight From Overweight

CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint
CRVO

TipRanks

a year ago

CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint

CRVO

MT Newswires

a year ago

Chardan Downgrades CervoMed to Neutral From Buy, Withdraws $55 Price Target

CRVO

MT Newswires

a year ago

Top Midday Decliners

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets
CRVO

Benzinga

a year ago

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

CRVO

MT Newswires

a year ago

Brookline Downgrades CervoMed to Hold From Buy; Shares Plunge

CRVO

MT Newswires

a year ago

CervoMed Shares Plunge After Dementia Treatment Fails to Meet Trial Endpoints

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
CRVO

GlobeNewswire

a year ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

CRVO

MT Newswires

a year ago

Roth Initiates CervoMed at Buy With $45 Price Target

CRVO

MT Newswires

a year ago

HC Wainwright Initiates CervoMed at Buy With $42 Price Target

CervoMed’s stock rises as FDA grants orphan drug status to dementia drug
CRVO

Pharmaceutical Technology

a year ago

CervoMed’s stock rises as FDA grants orphan drug status to dementia drug

CRVO

MT Newswires

a year ago

CervoMed Says it Gets FDA's Orphan Drug Designation for Neflamapimod to Treat Frontotemporal Dementia

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
CRVO

GlobeNewswire

a year ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

CervoMed Announces Key Senior Leadership Appointments
CRVO

GlobeNewswire

a year ago

CervoMed Announces Key Senior Leadership Appointments

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
CRVO

GlobeNewswire

a year ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
CRVO

GlobeNewswire

a year ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

CervoMed to Participate in Upcoming Investor Conferences
CRVO

GlobeNewswire

a year ago

CervoMed to Participate in Upcoming Investor Conferences

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
CRVO

GlobeNewswire

a year ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
CRVO

GlobeNewswire

a year ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
CRVO

GlobeNewswire

a year ago

CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

CervoMed Ends $20 Million Stock Sales Agreement with BTIG
CRVO

TipRanks

a year ago

CervoMed Ends $20 Million Stock Sales Agreement with BTIG

CRVO

MT Newswires

a year ago

CervoMed Files $250 Million Mixed Shelf

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
CRVO

GlobeNewswire

a year ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
CRVO

GlobeNewswire

a year ago

CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

With 35% ownership, insiders at CervoMed Inc. (NASDAQ:CRVO) are pretty optimistic and have been buying recently
CRVO

Simply Wall St.

a year ago

With 35% ownership, insiders at CervoMed Inc. (NASDAQ:CRVO) are pretty optimistic and have been buying recently

CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?
CRVO

Zacks

a year ago

CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?

CRVO

MT Newswires

a year ago

Chardan Initiates CervoMed at Buy With $55 Price Target

CervoMed to Participate in Upcoming Investor Conferences
CRVO

GlobeNewswire

a year ago

CervoMed to Participate in Upcoming Investor Conferences

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies
CRVO

GlobeNewswire

a year ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
CRVO

GlobeNewswire

a year ago

CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed Second Quarter 2024 Earnings: Beats Expectations
CRVO

Simply Wall St.

a year ago

CervoMed Second Quarter 2024 Earnings: Beats Expectations

Morgan Stanley Predicts up to ~230% Surge for These 2 ‘Strong Buy’ Stocks
CRVO

TipRanks

a year ago

Morgan Stanley Predicts up to ~230% Surge for These 2 ‘Strong Buy’ Stocks

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference
CRVO

GlobeNewswire

a year ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

CRVO

MT Newswires

a year ago

CervoMed Reports Plasma Biomarker Data Show Neflamapimod Lowers GFAP Levels

CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)
CRVO

GlobeNewswire

a year ago

CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)

CervoMed to Participate in the Emerging Growth Conference
CRVO

GlobeNewswire

a year ago

CervoMed to Participate in the Emerging Growth Conference

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
CRVO

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024
CRVO

GlobeNewswire

a year ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

CervoMed (NASDAQ:CRVO) Is In A Good Position To Deliver On Growth Plans
CRVO

Simply Wall St.

a year ago

CervoMed (NASDAQ:CRVO) Is In A Good Position To Deliver On Growth Plans

CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes
CRVO

GlobeNewswire

a year ago

CervoMed Announces Addition to Russell 2000® and Russell 3000® Indexes

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
CRVO

GlobeNewswire

a year ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

CRVO: Enrollment Set to Complete in Phase 2b RewinD-LB Trial in 2Q24; Topline Data in 4Q24…
CRVO

Zacks Small Cap Research

a year ago

CRVO: Enrollment Set to Complete in Phase 2b RewinD-LB Trial in 2Q24; Topline Data in 4Q24…

CRVO

MT Newswires

a year ago

--JonesTrading Starts CervoMed With Buy Rating, $70 Price Target

CRVO

MT Newswires

a year ago

CervoMed Names William Elder CFO

CervoMed to Appoint William Elder as Chief Financial Officer
CRVO

GlobeNewswire

a year ago

CervoMed to Appoint William Elder as Chief Financial Officer

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
CRVO

GlobeNewswire

a year ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

CRVO: $150 Million Financing Strengthens Balance Sheet; Topline Data for Phase 2b Trial in 4Q24…
CRVO

Zacks Small Cap Research

2 years ago

CRVO: $150 Million Financing Strengthens Balance Sheet; Topline Data for Phase 2b Trial in 4Q24…

Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
CRVO

GlobeNewswire

2 years ago

Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
CRVO

GlobeNewswire

2 years ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

CervoMed to Participate in Upcoming Investor Conferences
CRVO

GlobeNewswire

2 years ago

CervoMed to Participate in Upcoming Investor Conferences

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
CRVO

GlobeNewswire

2 years ago

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

CervoMed Inc.'s (NASDAQ:CRVO): Top Key Executive Sylvie Gregoire is the most bullish insider, and their stock value gained 29% last week
CRVO

Simply Wall St.

2 years ago

CervoMed Inc.'s (NASDAQ:CRVO): Top Key Executive Sylvie Gregoire is the most bullish insider, and their stock value gained 29% last week

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
CRVO

GlobeNewswire

2 years ago

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

CervoMed to Participate in the BIO CEO and Investor Conference
CRVO

GlobeNewswire

2 years ago

CervoMed to Participate in the BIO CEO and Investor Conference

CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board
CRVO

News Direct

2 years ago

CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
CRVO

GlobeNewswire

2 years ago

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
CRVO

GlobeNewswire

2 years ago

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now
CRVO

GlobeNewswire

2 years ago

Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now

CervoMed to Participate in the Emerging Growth Conference 67
CRVO

GlobeNewswire

2 years ago

CervoMed to Participate in the Emerging Growth Conference 67

Charter Communications (CHTR) Lags Q4 Earnings and Revenue Estimates
CRVO

Zacks

2 years ago

Charter Communications (CHTR) Lags Q4 Earnings and Revenue Estimates

LiveOne's (Nasdaq: LVO) Slacker Radio Partners With Legible Inc. Giving Access to Millions of Audiobooks and Ebooks for Its Members, Including Audiobook Previews for 1.5M+ Tesla Drivers
CRVO

NewMediaWire

2 years ago

LiveOne's (Nasdaq: LVO) Slacker Radio Partners With Legible Inc. Giving Access to Millions of Audiobooks and Ebooks for Its Members, Including Audiobook Previews for 1.5M+ Tesla Drivers

Unpacking Q3 Earnings: Bath and Body Works (NYSE:BBWI) In The Context Of Other Specialty Retail Stocks
CRVO

StockStory

2 years ago

Unpacking Q3 Earnings: Bath and Body Works (NYSE:BBWI) In The Context Of Other Specialty Retail Stocks

Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why
CRVO

Zacks

2 years ago

Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why

Share on Social Networks: